Preclinical research developed peptide-gold nanoparticles that disrupt the interaction between mutated KRAS and AGO2, potentially sensitizing KRAS-mutated colorectal cancer to chemo-immunotherapy. (Apoptosis)
Disrupting KRAS-AGO2 interaction may sensitize KRAS-mutant CRC to therapy
The CRC Digest